Holen Sie sich die Stockscreener-App
3.68
1.60%
-0.06
Handel nachbörslich:
3.68
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Investors in Altimmune, Inc. (ALT): Protect Your RightsContact Levi & Korsinsky Before October 6, 2025 - Newsfile
Securities Fraud Class Action Filed Against Altimmune, Inc. (ALT)Levi & Korsinsky Reminds Investors of October 6, 2025 - ACCESS Newswire
The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALT - PR Newswire
Altimmune (NASDAQ:ALT) Given New $24.00 Price Target at UBS Group - Defense World
Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright - Defense World
Altimmune (NASDAQ:ALT) Given New $18.00 Price Target at B. Riley - Defense World
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - Barchart.com
Transcript : Altimmune, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Altimmune, Inc. (ALT) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 6, 2025 - Newsfile
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Shareholders - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results - Benzinga
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Altimmune Faces Investor Lawsuit Over Disappointing Pemvidutide Trial – What Investors Need to Know - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - FinancialContent
Berger Montague PC Announces Class Action Filed Against Altimmune, Inc. (ALT) for Alleged Securities Violations - TradingView
Altimmune (ALT) Sees Adjusted Price Target by B. Riley Securitie - GuruFocus
UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating - MarketScreener
Altimmune, Inc. (NASDAQ:ALT) Q2 2025 Earnings Call Transcript - Insider Monkey
B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating - MarketScreener
Individual investors account for 51% of Altimmune, Inc.'s (NASDAQ:ALT) ownership, while institutions account for 48% - Yahoo Finance
Altimmune 2025 Q2 Earnings Improved Net Loss - AInvest
Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... - Yahoo Finance
Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cas - GuruFocus
Undervalued Innovators in Biotech: Assessing Altimmune and INmune Bio's High-Risk, High-Reward Potential - AInvest
Altimmune Reports Promising Trial Results and Financial Growth - TipRanks
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. - GlobeNewswire
Altimmune stock rises on promising Q2 report (ALT) - Seeking Alpha
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
What makes Altimmune Inc. stock price move sharplyHighest Potential Swing Stocks - thegnnews.com
Altimmune, Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Altimmune Q2 2025 beats EPS forecast, stock rises - Investing.com
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
Altimmune Announces Second Quarter 2025 Financial Results and Business Update - Yahoo Finance
Altimmune, Inc. Sued for Securities Law Violations – - GlobeNewswire
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
What moving averages say about Altimmune Inc.Weekly Growth Portfolio Performance Summary - Newser
Published on: 2025-08-11 21:36:11 - Newser
Altimmune, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & ... - Bluefield Daily Telegraph
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune Board Appoints Jerry Durso as Chairman - citybiz
Shareholders of Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your RightsALT - Barchart.com
Altimmune Appoints Jerry Durso as Chairman as Company Advances to Phase 3 Development of Pemvidutide - Quiver Quantitative
Altimmune appoints Jerry Durso as board chairman - Investing.com
Altimmune Board of Directors Appoints Jerry Durso as Chairman - Yahoo Finance
Analyzing recovery setups for Altimmune Inc. investorsShort-Term Sector Movement Forecast Generator - Newser
Heatmap analysis for Altimmune Inc. and competitorsWealth Accumulation Outlook for Safe Investors - Newser
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
Can Altimmune Inc. recover in the next quarterWeekly Chart Watchlist with Trade Guidance - Newser
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - Defense World
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Eastern Progress
Volatility clustering patterns for Altimmune Inc.Free Scalable Portfolio Growth Suggestions - Newser
Predicting Altimmune Inc. trend using moving averagesMachine Learning Intraday Signal Forecast - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.
Altimmune's Securities Fraud Litigation: A Cautionary Tale for Biotech Investors - AInvest
Faruqi & Faruqi investigates Altimmune securities class action lawsuit. - AInvest
ALT Investors Have the Opportunity to Lead the Altimmune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Combining price and volume data for Altimmune Inc.Free Buy Signal Based on Chart Analysis - Newser
Securities Fraud and Market Volatility: The Altimmune Case and Its Lessons for Biopharma Investors - AInvest
Altimmune Inc. stock momentum explainedAI Powered Buy Point Forecast Planner - Newser
Altimmune Inc. stock daily chart insightsReliable Setup Screener with Low Risk - Newser
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - PR Newswire
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):